接受细胞周期蛋白依赖性激酶4/6抑制剂治疗的乳腺癌患者骨转移放疗疗效
本研究分析了2018至2024年间398例接受CDK4/6抑制剂治疗的ER阳性HER2阴性乳腺癌骨转移患者,其中114例接受177程骨放疗(34程立体定向体部放疗和143程常规放疗)。接受骨放疗者中位无进展生存期为31.0个月对比未接受者26.3个月,2年无进展生存率57.1%对比53.2%(p=0.51),中位总生存期49.1个月对比40.5个月,3年总生存率63.7%对比55.0%(p=0.50),差异均未达统计学显著。
要点
- 接受骨放疗者中位无进展生存期31.0个月,未接受者26.3个月,2年无进展生存率57.1%对比53.2%(p=0.51)。
- 接受骨放疗者中位总生存期49.1个月,未接受者40.5个月,3年总生存率63.7%对比55.0%(p=0.50)。
- 接受放疗患者3年局部控制率为86.9%(95%CI 72.2-94.1%)。
核心结论
- 本研究呈现了迄今为止已发表的最大队列,即接受CDK4/6抑制剂联合骨定向放疗的乳腺癌患者。
- 尽管观察到的生存差异未达统计学显著,放疗在某些转移性乳腺癌患者中仍是一种可行的治疗方式。
研究设计与样本
- 分析2018至2024年间398例接受CDK4/6抑制剂治疗的ER阳性HER2阴性乳腺癌骨转移患者。
- 共114例接受177程骨放疗,与CDK4/6抑制剂同时或在其启动前6个月内进行,包括34程立体定向体部放疗和143程常规放疗。
主要发现
- 接受骨放疗者中位无进展生存期为31.0个月,未接受骨放疗者为26.3个月。
- 接受骨放疗者2年无进展生存率为57.1%(95%CI 46.3-66.6%),未接受骨放疗者为53.2%(95%CI 46.3-59.6%),p=0.51。
- 接受骨放疗者中位总生存期为49.1个月,未接受骨放疗者为40.5个月。
- 接受骨放疗者3年总生存率为63.7%(95%CI 51.5-73.5%),未接受骨放疗者为55.0%(95%CI 46.6-62.6%),p=0.50。
- 接受放疗患者3年局部控制率为86.9%(95%CI 72.2-94.1%)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In patients diagnosed withestrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer, bone metastasesemerge as theprimary siteofsignificant tumor burden. Cyclin-dependent kinase 4/6 (CDK4/6i) inhibitorsare thegold standard in this clinical scenario, while radiotherapy (RT) represents a valuable addition. However, data on the efficacy of this combination remain scarce. We aimed to evaluate efficacy of RT in bone metastatic breast cancer patients treated with CDK4/6 inhibitors. MATERIALS AND METHODS: 398 patients (pts) with ER-positive HER2-negative breast cancer with bone metastases treated with CDK4/6i between 2018-2024 were analyzed. A total of 114 pts received 177 bone RT concurrently with CDK4/6i or within 6 months before CDK4/6i initiation, including 34 courses of stereotactic-body RT and 143 courses of conventional RT. RESULTS: The median progression-free survival (PFS) in pts who received bone RT was 31.0 months, compared to 26.3 months in pts without bone RT. The 2-y PFS for pts with bone RT was 57.1 % [95 % CI: 46.3-66.6 %] vs. 53.2 % [95 % CI: 46.3-59.6 %] for patients without bone RT (p = 0.51). The median overall survival (OS) for pts who received bone RT was 49.1 months, compared to 40.5 months for pts without bone RT. The 3-y OS for pts with bone RT was 63.7 % [95 % CI: 51.5-73.5 %] vs. 55.0 % [95 % CI 46.6-62.6 %] for pts without bone RT (p = 0.50). The 3-y local control for irradiated patients was 86.9 % [95 % CI 72.2-94.1 %]. CONCLUSIONS: In this study, we present the largest cohort published to date of breast cancer patients who received CDK4/6i alongside bone-directed RT. Although the observed differences in survival were not statistically significant, RT remains a viable treatment modality in metastatic breast cancer in some patients.
引用
- Kubeczko M, Gabryś D, Rembak-Szynkiewicz J, et al. Efficacy of radiotherapy for bone metastasis in breast cancer patients treated with cyclin-dependent kinase 4/6 inhibitors. Radiother Oncol. 2024. PMID: 39566581. doi:10.1016/j.radonc.2024.110639
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。